Did you know that the first attempt at a cancer vaccine was all the way back in the 1800s? I am joined by Charles River experts Louise Brackenbury, Dan Rocca, and Mike Templin to discuss the fascinating science behind therapeutic cancer vaccines.

Clarification: Coley’s Toxin is not a vaccine in the traditional sense, but a compound developed by William Coley in the 19th century as a treatment for cancer, and is considered a precursor to modern cancer immunotherapy.

Spheroids are three dimensional cell models that can mimic some organs, tumors, and other biological systems for drug testing. Like organoids and organs-on-a-chip, spheroids are breaking in to drug development as a promising alternative to animal models. I am joined by Madhu Lal Nag, MBS PhD from the 3D in vitro model company InSphero, to discuss the development and future potential of these tiny cellular machines.

The agrochemical field has long relied on animal models to evaluate the safety and efficacy of substances, but there’s a growing demand to adopt new alternative methods (NAMs) that can further the industry while reducing the need for animal testing. However, questions remain as to their long-term viability.

Join Robert Landsiedel, Vice President of Experimental Toxicology and Ecology, and Susanne Kolle, Research Coordinator of Experimental Toxicology and Ecology at BASF, as they explain the benefits of NAMs, how they comply with the 3Rs principle, and the role collaboration is playing to push NAMs as a viable alternative to animals.

Show Notes

Alternative Methods

AMAP Strategic Partnerships

Animals in Research

Modernizing Drug Development

Agrochemical Testing Service for Approvals

Chemical Testing Services

Charles River Laboratories Announces Development of Nonclinical Virtual Control Groups with Sanofi to Reduce the Use of Animals

Charles River Laboratories, in Collaboration with MatTek Corporation, Awarded Grant from the Foundation for Chemistry Research and Initiatives to Advance Research Alternatives